Assertio Holdings, Inc. (NASDAQ:ASRT) Shares Purchased by CM Management LLC

CM Management LLC raised its holdings in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) by 23.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 400,000 shares of the company’s stock after buying an additional 75,000 shares during the period. CM Management LLC’s holdings in Assertio were worth $348,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ASRT. Captrust Financial Advisors purchased a new position in shares of Assertio in the 3rd quarter valued at $26,000. Sonora Investment Management Group LLC purchased a new position in Assertio in the fourth quarter valued at about $39,000. Thurston Springer Miller Herd & Titak Inc. lifted its stake in shares of Assertio by 33.7% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 67,500 shares of the company’s stock worth $59,000 after purchasing an additional 17,000 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Assertio during the third quarter worth about $177,000. Finally, Palumbo Wealth Management LLC boosted its position in shares of Assertio by 10.6% in the fourth quarter. Palumbo Wealth Management LLC now owns 205,598 shares of the company’s stock worth $179,000 after buying an additional 19,637 shares during the period. 48.96% of the stock is currently owned by hedge funds and other institutional investors.

Assertio Trading Down 3.5 %

Shares of ASRT opened at $0.78 on Friday. Assertio Holdings, Inc. has a one year low of $0.73 and a one year high of $1.80. The stock has a 50-day moving average price of $0.82 and a 200 day moving average price of $0.98. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.57 and a current ratio of 2.01. The company has a market capitalization of $74.65 million, a P/E ratio of -1.07, a P/E/G ratio of 3.25 and a beta of 0.81.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ASRT shares. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Assertio in a research report on Monday, December 16th. StockNews.com raised shares of Assertio from a “hold” rating to a “buy” rating in a research report on Wednesday, November 13th.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.